Drug Guide
Phenindione
Classification
Therapeutic: Anticoagulant
Pharmacological: Vitamin K antagonist
FDA Approved Indications
- Prevention and treatment of thromboembolic disorders, such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation-related embolism
Mechanism of Action
Inhibits synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, thereby impairing clot formation
Dosage and Administration
Adult: Typically 100-200 mg daily, divided into doses; dosage adjusted based on INR monitoring
Pediatric: Not commonly used; limited data available, consult specialist
Geriatric: Start with lower doses due to increased bleeding risk; monitor closely
Renal Impairment: Use with caution; dose adjustments may be necessary depending on renal function
Hepatic Impairment: Use with caution; hepatic function affects drug metabolism
Pharmacokinetics
Absorption: Well absorbed orally
Distribution: Widely distributed; crosses placental barrier
Metabolism: Metabolized in the liver by CYP enzymes
Excretion: Excreted primarily in urine
Half Life: Approximately 8-12 hours; varies among individuals
Contraindications
- Known hypersensitivity to phenindione or other vitamin K antagonists
- Active bleeding
- Bleeding disorders
Precautions
- Use with caution in patients with hepatic or renal impairment, bleeding tendencies, or recent surgery
- Monitor INR regularly
Adverse Reactions - Common
- Bleeding (Common)
- Nausea (Less common)
- Vomiting (Less common)
Adverse Reactions - Serious
- Hemorrhage (Serious and requires immediate attention)
- Decresed bone marrow function (Rare)
Drug-Drug Interactions
- Other anticoagulants, antiplatelet agents, NSAIDs, CYP450 inhibitors or inducers
Drug-Food Interactions
- Vitamin K-rich foods (e.g., green leafy vegetables) may reduce efficacy
Drug-Herb Interactions
- Herbal supplements affecting coagulation (e.g., garlic, ginkgo)
Nursing Implications
Assessment: Monitor bleeding, INR, hepatic and renal function
Diagnoses:
- Risk for bleeding
- Impaired tissue perfusion
Implementation: Administer as prescribed, educate patient on bleeding precautions
Evaluation: Regularly evaluate INR levels and adjust dose accordingly
Patient/Family Teaching
- Take medication exactly as prescribed
- Report signs of bleeding (e.g., unusual bruising, blood in stool or urine)
- Maintain consistent intake of vitamin K-rich foods
- Avoid alcohol and other medications that increase bleeding risk
- Schedule regular INR monitoring appointments
Special Considerations
Black Box Warnings:
- Significant bleeding risk; requires careful monitoring
Genetic Factors: Genetic polymorphisms in CYP2C9 can affect metabolism and dosing
Lab Test Interference: May interfere with certain coagulation assays
Overdose Management
Signs/Symptoms: Excessive bleeding, hematuria, gastrointestinal bleeding
Treatment: Discontinue drug, provide supportive care, administer vitamin K, consider fresh frozen plasma or prothrombin complex concentrates in severe cases
Storage and Handling
Storage: Store at room temperature, away from moisture and sunlight
Stability: Stable for the duration specified on the package; verify expiration date